New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Rhea-AI Summary

A new Veeva MedTech study reveals that 88% of medtech companies plan to modernize their postmarket quality management within three years. The 2025 benchmark report, surveying over 100 quality leaders, shows that 68% still rely on manual or legacy systems, potentially causing delays in addressing product issues. Key findings indicate that 38% of companies prioritize proactive and risk-based quality management, while 26% focus on scaling processes for growth. 75% believe advanced technology can drive automation for efficiency, and 62% see value in connecting quality management processes. However, emerging technologies like AI and automation show limited adoption at less than 3%. The study also highlights a significant training gap, with only 19% of respondents confident in their current training programs for postmarket quality teams.

Positive

• 88% of medtech companies planning to modernize quality management shows strong industry commitment to improvement
• 75% of companies recognize technology's potential for automation and efficiency
• Survey reveals clear strategic priorities with 38% focusing on proactive quality management
• 62% of companies understand the value of connected quality management processes

Negative

• 68% still rely on manual processes or legacy systems, risking delays and compliance issues
• Less than 3% have successfully implemented AI and automation technologies
• Only 19% have sufficient training programs for postmarket quality teams
• Current manual processes causing delays in addressing product issues and complaint handling backlogs

Industry focused on automation, connectivity, and reporting for proactive quality management

PLEASANTON, Calif., June 9, 2025 /PRNewswire/ -- The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality management within the next three years to improve compliance and drive innovation. This signals a shift toward modernization to reduce risk and foster a stronger culture of quality across the product lifecycle.

While the move to more scalable solutions is planned or underway for most, 68% of medtechs currently rely on manual processes, a mix of paper-based and electronic systems, or legacy on-premise solutions. This can cause delays in addressing product issues and lead to backlogs in complaint handling. Companies with slow response times to patient safety concerns incur significant risks in compliance, consumer trust, and brand reputation.

The research highlights opportunities for medtechs to streamline quality operations for proactive management and execution, including: 

An emphasis on proactive action. The primary drivers to advance quality are proactive and risk-based quality management (38%) and scaling processes to support growth (26%) to adapt to market changes. 

Technology viewed as an enabler. With more than half of medtechs working on manual processes, most respondents say advanced technology can drive automation for faster timelines and efficiency (75%), connections with other quality management system processes (62%), and advanced reporting for data-driven decision-making (61%). 

Generative AI, intelligent automation, and robotic process automation scarcely adopted. Less than 3% of companies have reliably applied these emerging technologies across their organizations. Despite limited adoption, there is strong optimism about the potential of these technologies, with improving timeliness and efficiency ranked as the top opportunities. 

Gaps in employee training exist. Only 19% of respondents say their training programs are sufficient to support postmarket quality teams for future success. This presents an opportunity to introduce an interactive learning approach that ensures employees receive real-time updates and guidance on job responsibilities.

"While initiatives are underway to simplify and connect medtech quality operations, the research reveals that many of the organizations surveyed are limited by legacy systems and manual processes," said Vishaka Rajaram, senior director of quality strategy at Veeva MedTech. "By aligning strategic goals with modern technology solutions, medtechs can move from reactive issue management to proactive risk prevention for greater speed and compliance."

The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed more than 100 quality medtech leaders, examining the medical device and diagnostic industry's progress, challenges, and opportunities in quality management. To learn more, read the benchmark report here. 

About Veeva Systems
Veeva (NYSE: VEEV) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-finds-88-of-medtechs-prioritizing-postmarket-quality-modernization-within-next-3-years-302475047.html

SOURCE Veeva Systems

FAQ

What percentage of medtech companies are prioritizing postmarket quality modernization according to Veeva's 2025 study?

According to Veeva's 2025 study, 88% of medtech companies are prioritizing postmarket quality modernization within the next three years.

What are the main challenges in medtech quality management identified in the Veeva (VEEV) report?

The main challenges include 68% still using manual or legacy systems, less than 3% adoption of AI and automation, and only 19% having sufficient training programs.

How many medtech companies currently use manual or legacy systems for quality management?

68% of medtech companies currently rely on manual processes, paper-based systems, or legacy on-premise solutions.

What percentage of medtech companies focus on proactive and risk-based quality management?

38% of medtech companies focus on proactive and risk-based quality management as their primary driver for advancement.

How many quality medtech leaders participated in Veeva's 2025 benchmark report?

The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed more than 100 quality medtech leaders.